Tarrytown, N.Y.-based Regeneron Pharmaceuticals said the FDA declined to approve its blood cancer therapy for two forms of lymphoma over concerns about the ongoing confirmatory trials.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
